These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5. Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772 [TBL] [Abstract][Full Text] [Related]
3. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523 [TBL] [Abstract][Full Text] [Related]
4. ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. Camporez JPG; Kanda S; Petersen MC; Jornayvaz FR; Samuel VT; Bhanot S; Petersen KF; Jurczak MJ; Shulman GI J Lipid Res; 2015 Mar; 56(3):526-536. PubMed ID: 25548259 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein A5 gene polymorphisms are associated with non-alcoholic fatty liver disease. Xu Y; Lu LL; Liu SS; Du SX; Zhu HL; Dong QJ; Xin YN Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):214-219. PubMed ID: 29735301 [TBL] [Abstract][Full Text] [Related]
7. The role of apolipoprotein A5 in non-alcoholic fatty liver disease. Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203 [TBL] [Abstract][Full Text] [Related]
8. Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters. Guo J; Miao G; Zhang W; Shi H; Lai P; Xu Y; Zhang L; Chen G; Han Y; Zhao Y; Liu G; Zhang L; Wang Y; Huang W; Xian X Theranostics; 2024; 14(5):2036-2057. PubMed ID: 38505614 [No Abstract] [Full Text] [Related]
9. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933 [TBL] [Abstract][Full Text] [Related]
10. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. Qiu X; Gao DH; Xiang X; Xiong YF; Zhu TS; Liu LG; Sun XF; Hao LP World J Gastroenterol; 2015 Jul; 21(26):8061-72. PubMed ID: 26185377 [TBL] [Abstract][Full Text] [Related]
11. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD. Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487 [TBL] [Abstract][Full Text] [Related]
12. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling. Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633 [TBL] [Abstract][Full Text] [Related]
13. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854 [TBL] [Abstract][Full Text] [Related]
14. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice. Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731 [TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454 [TBL] [Abstract][Full Text] [Related]
16. Fructose supplementation worsens the deleterious effects of short-term high-fat feeding on hepatic steatosis and lipid metabolism in adult rats. Crescenzo R; Bianco F; Coppola P; Mazzoli A; Tussellino M; Carotenuto R; Liverini G; Iossa S Exp Physiol; 2014 Sep; 99(9):1203-13. PubMed ID: 24972835 [TBL] [Abstract][Full Text] [Related]
17. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice. Lu H; Yuan X; Zhang Y; Han M; Liu S; Han K; Liang P; Cheng J Biomed Pharmacother; 2020 Sep; 129():110347. PubMed ID: 32535386 [TBL] [Abstract][Full Text] [Related]
18. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141 [TBL] [Abstract][Full Text] [Related]
19. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. Ganz M; Csak T; Szabo G World J Gastroenterol; 2014 Jul; 20(26):8525-34. PubMed ID: 25024607 [TBL] [Abstract][Full Text] [Related]
20. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts. Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]